Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision

AIMode News Desk · curated summary

August 13, 20261 min readHealth

Automated news aggregation. Headlines and summaries are gathered from public feeds; see our editorial standards for sourcing, corrections, and AI-assist disclosure.

Related coverage: Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision Fierce Biotech

About this story

This story was aggregated from Fierce Biotech. Headlines, summaries, and links are gathered automatically from public RSS feeds for your convenience.

Read the full story →

For agents:JSON record OpenAPI WebMCP llms.txt

Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision

About this story

More in Health

MU School of Medicine receives $1 million cancer research grant

Newborn screening for cancer risk could save lives. Should it be done?

UToledo Research Receives Funding from Stand Up To Cancer to Test Early Warning for Lung Cancer

Upcoming Events Spotlighting the Latest Advances in Cancer Research - National Cancer Institute